As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.
Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.
Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.